A new hairloss treatment using dermal exosomes can restore up to 90% of lost hair in mice. Users discuss potential human trials and compare it to Minoxidil and Finasteride.
A sugar gel containing 2-deoxy-D-ribose has shown promising hair regrowth results in mice, comparable to Minoxidil. Users are discussing the potential to buy and try this compound themselves.
Hairloss can be influenced by chronic low-level allergies, and treatments like fexofenadine or topical cetirizine may help with regrowth. The user avoids finasteride, dutasteride, and minoxidil, and has tried Regenera Activa and PRF sessions.
A 25-year-old male with DUPA (diffuse thinning including the donor area) has not seen improvement after 14 months on finasteride. He's considering switching to dutasteride (DUT) after advice from a hairloss YouTuber and is also contemplating trying RU58841.
Hairloss possibly caused by chlorine and heavy metals in water was addressed by using a shower filter, ketoconazole shampoo, and PRP sessions, which stopped the hairloss but did not lead to regrowth. Other users suggested similar experiences and solutions, emphasizing the importance of a good water filter and patience for potential regrowth.
A 22-year-old male experienced hairloss potentially linked to escitalopram, which stopped after switching to vortioxetine. His depressive symptoms improved with continued treatment.
Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.
The conversation is about the role of testosterone in hairloss and the effectiveness of different treatments. The conclusion is that DHT is the main culprit for hairloss, and finasteride has been proven to work long-term in maintaining and regrowing hair. Testosterone may have a minor effect, but it is not the primary cause of hairloss.
Hairloss treatments discussed include minoxidil, finasteride, dutasteride RU, derma rolling, pyrilutamide, cosmeRNA, hair systems, and essential oils. The user seeks information on additional treatments, safety profiles, and alternative options for androgenetic alopecia.
Hairloss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.
A user has been taking finasteride for 5 months with no improvement in diffuse hairloss and suspects high levels of prolactin, cortisol, progesterone, and DHEAS, as well as iron, might be contributing to the issue. They are also taking vitamin D to address a deficiency.
Exosome hair therapy involves injecting stem cell-derived exosomes into the scalp to boost hair follicle regeneration and repair. Exosomes, which are not stem cells but products of them, contain bioactive chemicals and specific growth factors that promote new blood vessel formation, increase cell proliferation, reduce inflammation, and improve tissue repair, all crucial for hair health.
Serum DHT is mostly inactive; sebum DHT is a better measure for hairloss. Users discuss using finasteride, dutasteride, and topical treatments like KX826 and RU58841 for better scalp DHT suppression.
The conversation discusses androgen receptor degraders for hairloss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
A user is concerned about hairloss from creatine and asks for precautions, mentioning treatments like Minoxidil, finasteride, and ketoconazole shampoo. Replies vary, with some users sharing personal experiences and others dismissing the concern.
The conversation discusses updates on hairloss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.
Melatonin is being discussed as a potential treatment for hairloss, with questions about its effectiveness and whether it should be used topically or orally. No specific conclusions or personal experiences were shared.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hairloss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
A 21-year-old male managed to control his hairloss using Nizoral, RU58841, and finasteride, but experienced increased scalp itchiness after starting creatine, which subsided upon stopping creatine. Users shared mixed experiences on whether creatine affects hairloss, with some reporting negative effects and others seeing no change or defending its benefits.
The conversation is about seeking updates on new hairloss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
The conversation discusses potential future hairloss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.
The conversation is a guide on treating hairloss, discussing finasteride and dutasteride to lower DHT, minoxidil for growth, ketoconazole shampoo for scalp health, and dermarolling for regeneration. RU58841 is mentioned as a DHT blocker but not recommended due to safety concerns.
The conversation discusses GT20029 as a potential cure for hairloss and includes information on specific treatments used. Minoxidil, finasteride, and RU58841 are mentioned as related treatments.
Isotretinoin may cause hairloss by increasing DHT through a precursor androgen, DHEAS. Treatments like topical antiandrogens (RU58841, pyrilutamide) and drugs increasing PPAR-y expression (pioglitazone) might prevent this hairloss.
User considers trying RU58841 for hairloss and asks for advice on its effectiveness and application. Responses vary, with some reporting positive results and others warning about potential risks or lack of change.